4.7 Article

Inhibition of breast cancer growth via miR-7 suppressing ALDH1A3 activity concomitant with decreasing breast cancer stem cell subpopulation

Journal

JOURNAL OF CELLULAR PHYSIOLOGY
Volume 235, Issue 2, Pages 1405-1416

Publisher

WILEY
DOI: 10.1002/jcp.29059

Keywords

breast cancer; cancer stem cells; miR-7; subpopulation

Funding

  1. National Natural Science Foundation of China [81572887]
  2. National key Research and development Program of China [2017YFA0205502]
  3. Foundation of Nanjing science and technology development plan [2016sc512020]
  4. Scientific Research Foundation of Graduate School of Southeast University [YBJJ1746]

Ask authors/readers for more resources

Breast cancer patients with high expression of aldehyde dehydrogenases (ALDHs) cell population have higher tolerability to chemotherapy since the cells posses a characteristic of breast cancer stem cells (BCSCs) that are resistant to conventional chemotherapy. In this study, we found that the ALDH-positive cells were higher in CD44(+)CD24(-) and CD44(+)CD24(-)ESA(+)BCSCs than that in both BT549 and MDA-MB-231 cell lines but microRNA-7 (miR-7) level was lower in CD44(+)CD24(-) and CD44(+)CD24(-)ESA(+)BCSCs than that in MDA-MB-231 cells. Moreover, miR-7 overexpression in MDA-MB-231 cells decreased ALDH1A3 activity by miR-7 directly binding to the 3 '-untranslated region of ALDH1A3; while the ALDH1A3 expression was downregulated in MDA-MB-231 cells, the expressions of CD44 and Epithelium Specific Antigen (ESA) were reduced along with decreasing the BCSC subpopulation. Significantly, enforced expression of miR-7 in CD44(+)CD24(-)ESA(+)BCSC markedly inhibited the BCSC-driven xenograft growth in mice by decreasing an expression of ALDH1A3. Collectively, the findings demonstrate the miR-7 inhibits breast cancer growth via suppressing ALDH1A3 activity concomitant with decreasing BCSC subpopulation. This approach may be considered for an investigation on clinical treatment of breast cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available